Summarized by Masters of Longevity from Swiss Biotech.
A biotech financing and clinical-development update describing advancement of an investigational cancer-prevention immunotherapy into a pivotal global trial, and the data and investor support behind that plan.
Key Takeaways
- Nouscom closed an oversubscribed €120 million Series D financing led by M Ventures and Revelation Partners.
- Proceeds will fund NOUS-209 through a single global registration-enabling trial targeting Lynch Syndrome carriers.
- Phase 1b/2 data showed all evaluable treated Lynch Syndrome carriers remained free of advanced adenomas and colorectal cancer at years 1 and 2.
